Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients.
about
Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 YearsIs there a role for consolidative radiotherapy in the treatment of aggressive and localized non-Hodgkin lymphoma? A systematic review with meta-analysis.Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtypeAre health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature.Current knowledge and future research directions in treatment-related second primary malignancies.Second malignancies among elderly survivors of cancer.Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy.Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alphaA Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor StudyComposite EBV negative peripheral T-cell lymphoma and diffuse large B-cell lymphoma involving the ileum: a case report and a systematic review of the literature.Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma: Past, Present, and Future.Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma.Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma.Front-line therapy for nonlocalized diffuse large B-cell lymphoma: what has been demonstrated and what is yet to be established.Synthesis and In vitro activity of ROMP-based polymer nanoparticles.Safe handling of parenteral cytotoxics: recommendations for ontario.The important role of radiation therapy in early-stage diffuse large B-cell lymphoma: time to review the evidence once again.Quality of life following treatment for B-cell lymphoma.Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors.Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy.Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors.The role of radiation therapy in the treatment of stage I-II diffuse large B-cell lymphoma.The importance of radiotherapy on diffuse large B cell lymphoma treatment: a current review.Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma.Predicting Organ-Specific Risk Interactions between Radiation and Chemotherapy in Secondary Cancer Survivors.Liposomal anthracycline chemotherapy and the risk of second malignancies in patients with Kaposi's sarcoma (KS).Quadri-lineage disease involving nodal B-cell marginal zone lymphoma, high-grade B-cell lymphoma, Kaposi's syndrome, and acute myeloid leukemia.Risk of second malignancies in patients with gastric marginal zone lymphomas of mucosa associate lymphoid tissue (MALT).Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma.Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients.Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.A Rare Differential Diagnosis of an Adrenal Mass: A Case Report.Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi.Cardiovascular mortality trends in non-Hodgkin's lymphoma: a population-based cohort study.Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors.Survival outcomes for head and neck squamous cell carcinoma arising after lymphoma.Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas
P2860
Q28264598-548F927E-AFB0-43A6-9DA1-A43CB2D31ABCQ31072157-A6BE0F1A-712B-426D-8FF4-DCE7BDF87620Q34488720-47F84E9C-C395-41F5-A6BA-12C3317C44E9Q34564716-725B82B0-B4A6-4345-8BB4-0C6DBC9D3D3CQ34604460-5116EBCF-B383-4163-B5A3-06C7582D970EQ35599802-6403BE09-931E-4296-ACD6-8372ABCB9BF7Q35613049-9CC6E28F-AB10-4568-B193-D43EFE0B24F3Q35847448-4DD9C53D-1CD5-471A-A239-DE2B429C344DQ35930640-6C0000E3-6D65-4855-AC6F-16D0CF1194B4Q36528733-2B9E2E5B-3CD6-4447-9681-0F6B257E0AF6Q36637659-88110E9D-B5B1-4BCA-AA92-A2E04FF7A6CAQ36672691-F48FAE21-6493-4D96-8875-4C92D3F90947Q36710973-B2D76C60-8898-415A-8FA1-2F9EC895452AQ36786000-9855443B-A9AA-4C81-A746-D1372AF78472Q36911493-752D75E7-8049-4FC9-84D5-1D8A0212AFF9Q37136999-9FBA8411-E39E-4070-8AD4-281595E7E79FQ37465333-3AA1E005-4E50-4960-8BF3-F1345FA7C63BQ37466453-D0D9B77A-0CCD-439C-8EE8-C47D9886A52FQ37934960-4D522033-C5AE-47A5-A22E-88C5E74BFA32Q37940556-A4205BF7-E72C-4C7A-BEB6-1BC8BD83477DQ37973345-09D3E51F-C4C7-4AB3-9A65-1A2DC9B611D9Q37976607-7C8323EE-AC6F-4D48-B858-9A8ADCB9DAACQ38093037-53F6DD5D-E5B2-4A27-BD0B-3B6E519ABDEEQ38125428-5381FA1C-4245-43DD-87E4-B24CFFF6842CQ38565503-CF4462DB-3128-452F-AAA3-ED0DDD961C9BQ41444373-474A18A7-62A0-453E-BFD2-88E9EDB4BE97Q41670896-A1984B79-181C-4F57-96F3-7E293E5CADF8Q42204251-E83465B7-434E-400F-8105-E426CEAA3CDCQ42881730-C0D70F18-94F5-4C99-B195-BFF75A36B14AQ44244956-A48007F0-93DF-4FF9-ADEC-D3B676BF9CA6Q44676921-D330AF58-E995-40E5-A0BC-538D5F462849Q44729105-CAD8DEBE-4C13-449A-89D7-E71CC1FFB59DQ46060624-B39BDE66-692E-4F5B-8E3D-2EC17B45B2BEQ47154442-BD4826A4-A707-4D9C-9E04-63E2FBD0C303Q48121946-E018D259-75C5-4CFE-ABCE-391B41DC3CB0Q48205375-8617E766-7A8F-4A75-8D97-0A6442793334Q50044245-98015226-93F3-4856-B712-D7254B3D2E45Q53495050-C022B380-04DE-4667-BB60-748148B40E7AQ58723337-7957CC38-27EB-46D5-9F08-D2C078FE8FC4
P2860
Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Second cancers and late toxici ...... cohort study on 2837 patients.
@en
Second cancers and late toxici ...... cohort study on 2837 patients.
@nl
type
label
Second cancers and late toxici ...... cohort study on 2837 patients.
@en
Second cancers and late toxici ...... cohort study on 2837 patients.
@nl
prefLabel
Second cancers and late toxici ...... cohort study on 2837 patients.
@en
Second cancers and late toxici ...... cohort study on 2837 patients.
@nl
P2093
P50
P1433
P1476
Second cancers and late toxici ...... cohort study on 2837 patients.
@en
P2093
André Bosly
Anne Sonet
Bertrand Coiffier
Christian Gisselbrecht
Felix Reyes
Groupe D'Etude Des Lymphomes De L'Adulte
Hervé Tilly
Marc André
Pauline Brice
Pierre Morel
P304
P356
10.1182/BLOOD-2003-04-1124
P407
P577
2003-10-23T00:00:00Z